Therabron Therapeutics and the NIH’s National Cancer Institute have entered into a Cooperative Research and Development Agreement (CRADA) in order to perform research on another member of the secretoglobin family called SCGB3A2. The title of the CRADA is; “Development of recombinant human secretoglobin 3A2 (SCGB3A2) as a biologic drug candidate: characterization of fundamental properties.” CC10, also known as SCGB1A1, and SCGB3A2 are members of the same family of proteins that share a similar structure and have many properties in common. Due to the company’s extensive know-how acquired in developing CC10, it is well-positioned to develop SCGB3A2 as a new drug candidate. The duration of the CRADA is 2.5 years, during which the company will produce the recombinant protein and characterize its properties in vitro, and the NCI will evaluate the recombinant protein in its specialized animal models of lung development and disease.
- Therabron Therapeutics Receives Orphan Drug Designation in the European Union for CG367.
- Therabron Therapeutics to Present at Stifel 2016 Healthcare Conference
- Therabron Therapeutics Receives from FDA Rare Pediatric Disease Designation for Lead Phase 2 Program in Preterm Infants
- Therabron Therapeutics to Present at Upcoming Industry and Investor Conferences
- Therabron Therapeutics Completes Enrollment of Phase 2 Clinical Trial for Lead Product Candidate CG100 for the Prevention of Chronic Lung Disease in Preterm Infants